DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Active lawsuits, DOJ investigations, FDA warning letters, and regulatory actions across GLP-1 telehealth providers. Updated as developments occur. Verify provider standing before you enroll.
Novo Nordisk filed a false-advertising lawsuit. Earlier in 2025, LegitScript certification was revoked, and DOJ scrutiny emerged over prescriptions allegedly written by unlicensed call-center staff under an async model.
High caution. Async prescribing without a licensed clinician review is the core allegation. Verify the prescriber is licensed in your state before enrolling.
FDA sent warning letters regarding compounded semaglutide marketing claims. Novo Nordisk separately pursued litigation over compounded product positioning after the shortage officially resolved.
Compounded semaglutide marketing is under regulatory pressure post-shortage. Confirm whether you are getting branded or compounded product, and the 503A/503B status.
FDA confirmed semaglutide and tirzepatide shortages resolved. Population-scale compounding is no longer protected by shortage exemption; FDA is enforcing 503A/503B limits more strictly.
Compounded GLP-1 supply is contracting. Providers relying on shortage-era compounding face supply and legal uncertainty. Branded or manufacturer-direct is the more durable route.
Patterns of billing complaints reported across consumer review platforms (auto-renewal, refund disputes). No formal regulatory action confirmed.
Watch-level, not litigation. Read auto-renewal terms carefully. Document cancellation requests in writing.
Editorial summary of publicly reported legal and regulatory developments, last reviewed 2026-05. Not legal advice. Allegations are not findings of liability. Providers may contest or resolve these matters; verify current status with primary sources.